Skip to main content
An official website of the United States government

Pre-Cancer Atlas (PCA)

A tumor (yellow) is shown in the background. Components within the microenvironment are overlaid on the tumor, including a dendritic cell (pink), a T-cell (blue), a fibroblast (purple and pink), a natural killer cell (dark blue), a regulatory t cell (aqua), blood vessels (red), a macrophage cell (red with a yellow center), and a myeloid cell (green).

The Pre-cancer Atlas (PCA) Research Centers are part of the Human Tumor Atlas Network (HTAN). HTAN, an NCI-collaborative program, is constructing multi-dimensional atlases of the cellular, morphological, molecular, and spatial features of human cancers and their surrounding microenvironments over time.

The atlases being created by HTAN describe important changes during cancer progression, such as the transition of precancers to malignant tumors, the evolution of metastatic cancer, and the development of treatment resistance.

HTAN is supported by the NCI Division of Cancer Prevention (DCP), NCI Division of Biology (DCB), the NCI Division of Cancer Treatment and Diagnosis (DCTD), and the NCI Center for Strategic Science Initiatives (CSSI).

On This Page

  • All Heading 2s will automatically be pulled in to this list.
  • Do not edit the content on this template.

About Pre-Cancer Atlas

The Pre-cancer Atlas (PCA) Research Centers, along with the Human Tumor Atlas (HTA) Research Centers and a Data Coordinating Center (DCC), make up HTAN. Each PCA Research Center will create a 2D/3D precancer atlas of a pre-cancerous lesion, focusing on how it changes into cancer.

PCA Research Centers have three major tasks:

  • Collecting, processing, and labeling biospecimens.
  • Studying the molecular, cellular, and spatial details of the lesions.
  • Analyzing and modeling the data.

PCA Research Centers will collaborate with other components of HTAN to make the data and analytical tools available to the research community.

Grantee Details

PI Name Sort descending PI Organization Title Grant Number Program Official
Chak, Amitabh

Case Western Reserve University
United States

Pathways of Injury and Repair in Barrett's Carcinogenesis 5P01CA269019-03 Asad Umar, D.V.M., Ph.D.
Chan, Andrew T

Massachusetts General Hospital
United States

MGH- PROSPECT: Pathways, Risk factors, and mOleculeS to Prevent Early-onset Colorectal Tumors 3OT2CA297680-01S1 Asad Umar, D.V.M., Ph.D.
Chan, Alexandre

University Of California-Irvine
United States

Neurotrophic strategy to mitigate chemotherapy-related brain injury 5R01CA276212-03 John Clifford, Ph.D.
Chan, Alexandre

University Of California-Irvine
United States

Neurotrophic strategy to mitigate chemotherapy-related brain injury 5R01CA276212-03 John Clifford, Ph.D.
Chan, Daniel Wanyui

Johns Hopkins University
United States

Development of a panel of multiplex biomarkers for the early detection of pancreatic ductal adenocarcinoma and high-risk lesions 5U01CA274514-03 Matthew Young, Ph.D.
Chan, Andrew T

Massachusetts General Hospital
United States

Precision Prevention Research Program 5R35CA253185-06 Asad Umar, D.V.M., Ph.D.
Chan, Daniel Wanyui

Johns Hopkins University
United States

BCC for Prostate Cancer: Discovery and Translation of Biomarkers for Clinical Unmet Needs 5U2CCA271895-03 Indu Kohaar, Ph.D., M.Phil., M.Sc.
Chapkin, Robert Stephen

Texas A&M Agrilife Research
United States

Targeting plasma membrane spatial dynamics to suppress aberrant Wnt signaling 5R01CA244359-05 Amit Kumar, Ph.D.
Chen, Ru

Baylor College Of Medicine
United States

BLOOD-BASED PROTEOMIC ASSAY FOR PANCREATIC CANCER DETECTION 4UH3CA292130-02 Claire Zhu, Ph.D.
Chen, Grace Y.

University Of Michigan At Ann Arbor
United States

Targeting cancer stem-like cells and inflammation for colon cancer chemoprevention 5R21CA273646-02
Cheville, Andrea Lynne

Mayo Clinic Rochester
United States

Achieving Safe, Comprehensive, Digitally-Enabled Cancer Pain managemeNT” (ASCENT) Clinical Trial 5R33CA278594-04 Brennan Streck, Ph.D., RN, M.P.H.
Cheville, Andrea Lynne

Mayo Clinic Rochester
United States

Achieving Safe, Comprehensive, Digitally-Enabled Cancer Pain managemeNT” (ASCENT) Clinical Trial 5R33CA278594-04 Brennan Streck, Ph.D., RN, M.P.H.
Chiang, Cheng-Ming

Ut Southwestern Medical Center
United States

Small Compound Inhibitors Targeting HPV Genome Replication 1R01CA288743-01A1
Chibwesha, Carla J

Univ Of North Carolina Chapel Hill
United States

Acceptability and feasibility of combination treatment for cervical precancer among South Africa women living with HIV 5R01CA250850-05 Vikrant Sahasrabuddhe, M.B.B.S., M.P.H., Dr.P.H.
Chinnaiyan, Arul M

University Of Michigan At Ann Arbor
United States

Michigan-VUMC Biomarker Characterization Center 5U2CCA271854-04 Indu Kohaar, Ph.D., M.Phil., M.Sc.